Background: Studies have reported worse overall survival (OS) for adenosquamous carcinoma (ASC) compared to adenocarcinoma (AC) of the colon, but none have analyzed a national dataset for over 30 years.
Methods: The National Cancer Database was queried from 2004 to 2016 for patients with ASC and AC of the colon. Kaplan-Meier survival analysis was performed to assess OS. Descriptive variables were evaluated using independent T-test and Chi-square analyses.
Results: 332 ASC patients were compared to 496,950 AC patients. AC patients were older than ASC patients (68.6 vs. 64.4 years); p < 0.001. Most ASC cancers presented with stage IV (41.3%) and poorly-differentiated disease (57.5%) compared to AC (22.4% and 17.7%). OS of the ASC cohort was 13.9 months. Median OS for stage IV AC versus stage IV ASC was significantly better (14.1 vs. 8.0 months); p < 0.0001.
Conclusion: This is the largest national database study to compare ASC with AC. Our findings confirm that unlike AC, ASC most frequently presents late stage, as poorly-differentiated lesions, and have worse OS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjsurg.2020.07.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Collision-type adenosquamous carcinoma of the colon with signet-ring adenocarcinoma: A rare case report.
Int J Surg Case Rep
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address:
Introduction And Importance: Adenosquamous carcinoma (ASC) of the colon is a rare malignancy, representing approximately 0.06 % of colorectal cancers (CRC). It is characterized by the coexistence of adenocarcinoma and squamous cell carcinoma components.
View Article and Find Full Text PDFOrganoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment.
Drug Resist Updat
January 2025
Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 518107, China; The Biobank, Scientific Research Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong 518107, China. Electronic address:
Article Synopsis
- Organoids were created from a patient's primary tumor and metastatic lymph nodes, accurately mirroring the tumor's characteristics.
- Drug testing on these organoids showed distinct differences in how they responded to treatments based on their origin (primary vs. metastatic).
- This personalized approach to using organoids aids in making informed treatment decisions for gastric cancer, potentially improving patient outcomes.
Low-Grade Adenosquamous Carcinoma of the Breast: A Single-Center Retrospective Study and a Systematic Literature Review.
Cancers (Basel)
December 2024
Department of Pathology, Turku University Hospital, 20520 Turku, Finland.
(1) Low-grade adenosquamous carcinoma (LGASC) is a rare subtype of metaplastic breast carcinoma (MpBC), accounting for fewer than 0.05% of breast cancer cases. Unlike the typically aggressive nature of MpBCs, LGASC is an indolent tumor with an excellent prognosis.
View Article and Find Full Text PDFThe deep learning radiomics nomogram helps to evaluate the lymph node status in cervical adenocarcinoma/adenosquamous carcinoma.
Front Oncol
December 2024
Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
Objectives: The accurate assessment of lymph node metastasis (LNM) can facilitate clinical decision-making on radiotherapy or radical hysterectomy (RH) in cervical adenocarcinoma (AC)/adenosquamous carcinoma (ASC). This study aims to develop a deep learning radiomics nomogram (DLRN) to preoperatively evaluate LNM in cervical AC/ASC.
Materials And Methods: A total of 652 patients from a multicenter were enrolled and randomly allocated into primary, internal, and external validation cohorts.
The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR-TKI-Resistant Mice.
Can Respir J
December 2024
Department of Rehabilitation, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
This study aimed to investigate the effect of Fuzheng Yiai Decoction (FZYA) on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) drug resistance in lung adenosquamous carcinoma (ASC). The expression of thyroid transcription factor 1 (TTF1) and p63 in tumor cells was observed by immunofluorescence staining. Meanwhile, 25 nude mice successfully inoculated with the human lung ASC cell line NCI-H596 were randomly divided into five groups, namely, the model, gefitinib, low-, medium-, and high-dose FZYA with gefitinib groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!